wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q50323773-2A17A1BE-3AFD-4D17-8100-E4540B307813
Q50323773-2A17A1BE-3AFD-4D17-8100-E4540B307813
BestRank
Statement
http://www.wikidata.org/entity/statement/Q50323773-2A17A1BE-3AFD-4D17-8100-E4540B307813
Response to baricitinib therapy in patients with rheumatoid arthritis with inadequate response to csDMARDs as a function of baseline characteristics.
P2860
Q50323773-2A17A1BE-3AFD-4D17-8100-E4540B307813
BestRank
Statement
http://www.wikidata.org/entity/statement/Q50323773-2A17A1BE-3AFD-4D17-8100-E4540B307813
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
4f8d150f810152f824e9ffcffdad4d1764898dfc
P2860
Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study.